Brivaracetam: A Newly Approved Medication for Epilepsy

References

• Von Rosenstiel P. Brivaracetam (UCB 34717). Neurotherapeutics 4, 84–87 (2007).
   PubMed Web of Science ®Google Scholar
• Von Rosenstiel P, Perucca E. Chapter 35: Brivaracetam. In: The Treatment of Epilepsy (3rd Edition). Shorvon SD, Perucca E, Engel J ( Eds). Wiley-Blackwell, NJ, USA, 447–457 (2009).
   Google Scholar
• Rogawski MA. Brivaracetam: a rational drug discovery success story. Br. J. Pharmacol. 154, 1555–1557 (2008).
   PubMed Web of Science ®Google Scholar
• UCB Pharma. www.ucb.com.
   Google Scholar
• Search studies: brivaracetam. https://clinicaltrials.gov/ct2/results?term=brivaracetam&pg=1 (2017).
   Google Scholar
• Search clinical trials: brivaracetam. www.clinicaltrialsregister.eu/ctr-search/search?query=Brivaracetam
   Google Scholar
• Briviact US Prescribing Information. UCB, Brussels, Belgium (2017). www.briviact.com/briviact-PI.pdf.
   Google Scholar
• Briviact EU Prescribing Information. UCB, Brussels, Belgium (2016). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003898/WC500200206.pdf.
   Google Scholar
• Kenda BM, Matagne AC, Talaga PE et al. Discovery of 4-substituted pyrrolindone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. 47, 530–549 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101, 9861–9866 (2004).
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu D, Kenda B et al. Anti-convulsive and anti-epileptic properties of brivaracetam (UCB 24714), a high affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 154, 1662–1671 (2008).
   PubMed Web of Science ®Google Scholar
• Zona C, Pieri M, Carunchio I et al. Brivaracetam (ucb 34714), a high affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 154, 1662–1671 (2008).
   PubMed Web of Science ®Google Scholar
• Mercier J, Holden D, Deo AK et al. Brivaracetam achieves brain SV2A occupancy faster than levetiracetam. Epilepsy Curr. 15(Suppl. 1), 343 (2015).
   Google Scholar
• Pack AM. Brivaracetam, a novel antiepileptic drug: is it effective and safe? Results from one Phase III randomized trial. Epilepsy Curr. 14(4), 196–198 (2014).
   PubMed Web of Science ®Google Scholar
• Gillard M, Fuks B, Leclerq K et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse, and human brain: relationship to anti-convulsant properties. Eur. J. Pharmacol. 664, 36–44 (2011).
   PubMed Web of Science ®Google Scholar
• Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, MN, 1940–1980. Epilepsia 32, 429–445 (1991).
   PubMed Web of Science ®Google Scholar
• Thurman DJ, Beghi E, Begley CE et al. ILAE Commission on Epidemiology. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 52(Suppl. 7), 2–26 (2011).
   PubMed Web of Science ®Google Scholar
• Epilepsy across the spectrum: promoting health and understanding (2012). http://iom.nationalacademies.org/Reports/2012/Epilepsy-Across-the-Spectrum.aspx#sthash.1w0ZE4E5.dpuf.
   Google Scholar
• Yates SL, Fakhoury T, Liang W et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 52, 165–168 (2015).
   PubMed Web of Science ®Google Scholar
• Wiebe S, Blume WT, Girvin GT et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 345, 311–318 (2001).
   PubMed Web of Science ®Google Scholar
• Jobst BC, Cascino G. Resective epilepsy surgery for drug-resistant focal epilepsy. JAMA 313(3), 285–293 (2015).
   PubMed Web of Science ®Google Scholar
• von Rosenstiel P, Perucca E. Chapter 35: Brivaracetam. In: The Treatment of Epilepsy (3rd Edition). Shorvon SD, Perucca E, Engel J ( Eds). Wiley-Blackwell, NJ, USA (2009).
   Google Scholar
• Zona C, Pieri M, Klitgaard H et al. Ucb 34717, a new pyrolidone derivative, inhibits Na+-currents in rat cortical neurons in culture. Epilepsia 45(Suppl. 7), 146 (2004).
   Google Scholar
• Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res. Rev. 19(2), 180–222 (1994).
   PubMed Web of Science ®Google Scholar
• Margineanu DG, Kenda B, Michel P et al. Ucb 24717, a new pyrrolidone derivative: comparison with levetiracetam in hippocampal slice epilepsy models in vitro. Epilepsia 44(Suppl. 9), 261 (2003).
   PubMedGoogle Scholar
• Shorvon SD. Chapter 48: Piracetam. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Fish D, Perucca E et al. ( Eds). Wiley–Blackwell, NJ, USA, 489–495 (2004).
   Google Scholar
• Zhou Q, Hu CY, Zhang W, Huang YH. Brivaracetam add-on therapy for epilepsy (Protocol). Cochrane Database Syst. Rev. (2015). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011501/epdf
   Google Scholar
• Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J. Neural. Transm. 114, 1547–1551 (2007).
   PubMed Web of Science ®Google Scholar
• Wasterlain C, Suchomelova L, Matagne A et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia 46, 219–220 (2005).
   Web of Science ®Google Scholar
• Lamberty Y, Ardid D, Eschalier A et al. A new pyrrolidone derivative UCB 24717 is effective in neuropathic pain models in rats: comparison with gabapentin. J. Pain 4(Suppl.), 53 (2003).
   Google Scholar
• Margineanu DG, Klitgaard H. Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. Seizure 18, 453–456 (2009).
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Rolan P, Connell J et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 63(6), 680–688 (2007).
   PubMed Web of Science ®Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 66, 71–75 (2008).
   PubMed Web of Science ®Google Scholar
• Hulhoven R, Scheen A, Watanabe J et al. Bioavailability and safety of the intravenous administration of brivaracetam. Epilepsia 49(Suppl. 7), 438 (2008).
   PubMedGoogle Scholar
• Sargentini-Maier ML, Espie P, Coquette A et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand in healthy subjects. Drug Metab. Dispos. 36, 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Sokalski A, Boulanger P et al. Brivaracetam disposition in renal impairment. J. Clin. Pharmacol. 52, 1927–1933 (2012).
   PubMed Web of Science ®Google Scholar
• LaCroix B, Rosenstiel P, Sargintini-Maier M-L. Population pharmacokinetics of brivaracetam in patients with partial epilepsy. Epilepsia 48(Suppl. 6), 333 (2007).
   Google Scholar
• Stockis A, Watanabe S, Rouits E et al. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 Genotype. Drug Metab. Pharmacokinet. 29, 394–399 (2014).
   PubMed Web of Science ®Google Scholar
• Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam, disposition in mild to severe hepatic impairment. J. Clin. Pharmacol. 53(6), 633–641 (2013).
   PubMed Web of Science ®Google Scholar
• Stockis A, Wantanabe S, Sheen A et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab. Dispos. 44, 792–799 (2016).
   PubMed Web of Science ®Google Scholar
• Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia 55(3), e27–e31 (2014).
   PubMed Web of Science ®Google Scholar
• Shoemaker R, Wade J, Stockis A. Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial onset seizures. J. Clin. Pharmacol. 56(12), 1591–1602 (2016).
   PubMed Web of Science ®Google Scholar
• Chanteux H, Kervyn S, Gerin B et al. In vitro pharmacokinetic profile of brivaracetam (BRV) reveals low risk of drug–drug interaction (DDI) and unrestricted brain permeability (P4.276). Neurology 84(Suppl. 14), (2015).
   Google Scholar
• Kasteleijn-Nolst T, Genton P, Parain D et al. Evaluation of brivaracetam, a novel SV2A ligand in the photosensitivity model. Neurology 69, 1027–1034 (2007).
   PubMed Web of Science ®Google Scholar
• Wasterlain GC, Suchomelova L, Matagne A et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia 46(Suppl. 8), 219 (2005).
   Google Scholar
• Klein P, Biton V, Dilley D et al. Safety/tolerability of adjunctive intravenous brivaracetam as infusion of bolus in patients with epilepsy. Epilepsy Curr. 14(Suppl. 1), 389 (2014).
   Google Scholar
• Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 50(Suppl. 12), 49–50 (2009).
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 75(6), 519–525 (2010).
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a Phase IIb, randomized, controlled trial. Epilepsia 54(1), 89–97 (2013).
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Erhahn KJ, Blaszcyck B et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 55(1), 47–56 (2014).
   PubMed Web of Science ®Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a Phase III randomized, double blind, placebo controlled trial. Epilepsia 55(1), 57–66 (2014).
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van Paesschen W et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a Phase III double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 55(1), 38–46 (2014).
   PubMed Web of Science ®Google Scholar
• Klein P, Schiemann J, Sperling MR et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 56(12), 1890–1898 (2015).
   PubMed Web of Science ®Google Scholar
• French JA, Wang S, Warnock B, Tem N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 51(10), 1936–1943 (2010).
   PubMed Web of Science ®Google Scholar
• Yates PI, French J, Edrich P et al. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 47, 77–90 (2001).
   PubMed Web of Science ®Google Scholar
• Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16, 296–304 (2007).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Gevins A, Leese PT et al. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia 52(2), 264–272 (2011).
   PubMed Web of Science ®Google Scholar
• Rogawski MA. A new SV2A ligand for epilepsy. Cell 167, 587 (2016).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Mameniškienė R, Quarato PP et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 87(3), 314–323 (2016).
   PubMed Web of Science ®Google Scholar
• Markham A. Brivaracetam: first global approval. Drugs 76(4), 517–522 (2016).
   PubMed Web of Science ®Google Scholar
• Kälviäinen R, Genton P, Andermann E et al. Brivaracetam in Unverricht–Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia 57(2), 210–221 (2016).
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Cagnetti C, Foschi N et al. Brivaracetam add-on for partial-onset seizures in 3 pooled clinical studies. Neurology 86(14), 1344–1352 (2016).
   PubMed Web of Science ®Google Scholar
• Stockis A, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. (113), 19–27 (2015).
   PubMedGoogle Scholar
• Stockis A, Brodie M et al. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. Epilepsy Res. (128), 163–168 (2016).
   PubMedGoogle Scholar
• Source: US FDA. FDA approves briviact to treat partial onset seizures. Press release: www.fda.gov/newsevents/newsroom/pressannouncements/ucm486827.htm.
   Google Scholar
• Drug Enforcement Administration Department of Justice. Schedules of Controlled Substances placement of brivaracetam into Schedule V. Interim final rule with request for comments. Fed. Regist. 81(92), 29487–29492 (2016).
   PubMedGoogle Scholar
• Russo E, Citaro R, Mula M. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. Expert Opin. Drug Discov. 12(11), 1169–1178 (2017).
   PubMed Web of Science ®Google Scholar
• American Academy of Neurology (AAN). Annual Meeting Abstracts Publication. www.aan.com.
   Google Scholar
• American Epilepsy Society (AES). AES meeting abstracts. 67th Annual Meeting of the American Epilepsy Society (AES). Washington, DC, USA, 6–10 December 2013. www.aesnet.org.
   Google Scholar
• Steinig I, von Podewils F, Moddel G et al. Post marketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia 58(7), 1208–1221 (2017).
   PubMed Web of Science ®Google Scholar
• Milovanocic JR, Jankovic SM, Pejcic A et al. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin. Pharmacother. 18, 1381–1389 (2017).
   PubMed Web of Science ®Google Scholar
• Klitgaard H, Matagne A, Nicholas JM et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 57, 538–548 (2016).
   PubMed Web of Science ®Google Scholar
• Finnema SJ, Mercier J, Naganawa M et al. Brivaracetam enters the brain faster than levetiracetam: a PET study in healthy volunteers. Neurology 88, p6.233 (2017).
   Web of Science ®Google Scholar
• Nicholas JM, Hannestad J, Holden D et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57(2), 201–209 (2016).
   PubMed Web of Science ®Google Scholar
• Moseley BD, Sperling MR, Asadi-Pooya AA et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three Phase III studies. Epilepsy Res. 127, 179–185 (2006).
   Google Scholar
• Klein P, Tyrikova I, Brazdil M et al. Brivaracetam for the treatment of epilepsy. Expert Opin. Pharmacother. 17, 283–295 (2016).
   PubMed Web of Science ®Google Scholar
• Toledo M, Whitesides J, Schiemann J et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia 57, 1139–1151 (2016).
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA, Sperling MR, Chung S et al. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: a post hoc study. Epilepsy Res. 131, 70–75 (2017).
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Steinig I, Willems L et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 70(Pt A), 177–181 (2017).
   PubMedGoogle Scholar
• Niquet J, Suchomelova L, Thompson K et al. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. Epilepsia 58(7), 1199–1207 (2017).
   PubMed Web of Science ®Google Scholar
• Brigo F, Bragazzi N, Nardone R et al. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. Seizure 42, 29–37 (2016).
   PubMed Web of Science ®Google Scholar
• Zhu L, Chen D, Xu D et al. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: an indirect comparison. Seizure 51, 121–132 (2017).
   PubMed Web of Science ®Google Scholar
• French J. Will brivaracetam help my patient? Only time will tell. Epilepsy Curr. 17, 35–36 (2017).
   PubMed Web of Science ®Google Scholar
• Klein P. Author response to epilepsy current commentary “Will brivaracetam help my patient? Only time will tell”. Neurology (2017). http://n.neurology.org/content/author-response-epilepsy-current-commentary-will-brivaracetam-help-my-patient-only-time-will.
   Google Scholar
• Kälviäiinen R, Genton P, Andermann E et al. Brivaracetam in patients with Unverricht–Lundborg disease: results from two randomized, placebo-controlled, double-blind studies. Epilepsia 50(Suppl. 10), 47 (2009).
   PubMedGoogle Scholar
• 28th International Epilepsy Congress (IEC), Budapest, Hungary, 28 June–2 July 2009.
   Google Scholar